Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Open Access

Automated GMP-Compatible Production of Universal CAR Tregs for Organ-Targeted Tolerance Induction

View Full Paper
Ask AI
Bookmark
Share

Authors

KLKavitha M. LakshmiAJAlexandra von Jutrzenka-TrzebiatowskiLLLiliana R. Loureiro

Discussion

Loading...

Member takes

Overview

Automated process generates high-purity CAR Tregs, suggesting promise for targeted tolerance in GvHD.

Key Points

  • RevCAR Tregs exhibited a median therapeutic yield of 602 × 10⁶ cells, ensuring enough functional cells for treatments.
  • Manufacturing runs achieved a high purity of 91.9%, maintaining characteristics essential for effective immunosuppression.
  • Automated, GMP-compatible methods ensured scalable production, vital for future clinical applications.
  • The RevCAR system indicates potential for off-the-shelf Treg therapies to manage immune-mediated diseases effectively.

Cite This Study

Lakshmi et al. (2025) studied this question.

synapsesocial.com/papers/68af7b2a7567bf4f94ff346ahttps://doi.org/10.21203/rs.3.rs-7416434/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revolutionizing Allogeneic Graft Tolerance Through Chimeric Antigen Receptor-T Regulatory Cells2025 · 6 citations
  2. 2First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation2025 · 6 citations
  3. 3Recent advances in universal chimeric antigen receptor T cell therapy2025 · 30 citations
  4. 4Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma2025
  5. 5Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy2025